Dr. Kimberly L. Blackwell on a Promising HER2 Breast Cancer Treatment
Kimberly L. Blackwell, MD, professor of Medicine, assistant professor of Radiation Oncology, Duke Cancer Institute, discusses upcoming trials for the HER2-antibody margetuximab.
Kimberly L. Blackwell, MD, professor of Medicine, assistant professor of Radiation Oncology, Duke Cancer Institute, discusses upcoming trials for the HER2-antibody margetuximab. She says the drug was initially tested in both phase I and II trials, though the trials are being repeated to test margetuximab’s effectiveness on HER2-positive breast cancer.
Blackwell also says that if approved, margetuximab could benefit patients with HER2 over-expression that are not eligible for trastuzumab.
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More
